Diffusion settles proxy contest with LifeSci; may appoint director if no deal by July 2023

CervoMed Inc.

LifeSci Special Opportunities withdraws its director nominees and will vote for Diffusion's slate at Dec 30 annual meeting.
If no strategic transaction (e.g., sale, merger) completed by July 1, 2023, Diffusion must appoint a LifeSci-designated director.
LifeSci, owning ~4.8% of DFFN shares, agrees to standstill and voting commitments through at least Dec 31, 2024.
Diffusion to reimburse LifeSci up to $50,000 for expenses related to nomination and negotiation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CervoMed Inc. entered into Agreement with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (effective 2022-12-15).

Action: entry
Agreement: settlement
Counterparty: LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, Diffusion Pharmaceuticals Inc. (the “ Company ”) entered into a binding settlement agreement (the “ Agreement ”) with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (collectively, “ LifeSci Special Opportunities ”)

View on SEC.gov

Browse all material agreements →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-029279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.